News
Dr. Voermans secures funding for extension of LAMA2-CMD natural history study
In 2022, Dr. Nicol Voermans and her team at Radboud UMC, Netherlands, launched the LASTSTRONG natural history study. With new…
News
-
![]()
News
-
![]()
Research updates
Modalis Therapeutics advances a novel gene therapy for LAMA2-CMD
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
-
![]()
News
France’s new LAMA2-CMD natural history study
LAMA2-France and Partners launch landmark LAMA2-CMD natural history study in France. The first French natural history study focused on LAMA2-CMD…
-
![]()
News
SEAL Therapeutics joins the fight!
SEAL Therapeutics was established in late 2021 by Prof. Markus Rüegg, Dr. Judith Reinhard, both from the Biozentrum, and Dr.…
-
![]()
News
Rico Verhoeven Meet and Greet
Heavyweight kickboxing world champion Rico Verhoeven met up with some of the LAMA2-CMD family in The Netherlands last December 2023. …
-
![]()
News
Dr Foley’s new research project to identifiy relevant biomarkers for LAMA2-CMD
Dr Reghan Foley has recently started a new research project in collaboration with the University College Cork / Cork’s University…
The driving forces behind Lama2.com
View all partners
